News

HHS slashes funding for mRNA vaccine development
US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency said Tuesday.
What is an mRNA vaccine, and why is it controversial?
Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to manufacture a protein, a piece of the virus. That causes the body to create its own antibodies against the virus.
RFK Jr. halts $500 million for mRNA vaccine research
HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine development projects that use mRNA technology.
RFK Jr. Cancels $500M in mRNA Vaccine Research Projects
U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has canceled nearly $500 million in grants and contracts meant to support mRNA vaccine development, the agency announced Tuesday.
Kennedy to halt $500 million in vaccine projects
Kennedy Jr. announced plans Tuesday to cancel $500 million in vaccine development projects. In a statement from his office, the longtime vaccine critic said all projects to be halted use mRNA technology.
RFK announces cuts to $500 million in mRNA vaccine funding
Kennedy Jr. announced cuts to 22 programs working to develop mRNA vaccines. Niki Gunter. More Videos
RFK Jr. cancels nearly $500 million in funds for mRNA vaccine development
Health and Human Services Secretary Robert F. Kennedy Jr. is halting nearly $500 million in funding to develop vaccines using mRNA technology. Dr. Jon LaPook reports.
Medical experts react to RFK Jr. canceling $500M in vaccines development projects
Robert F. Kennedy Jr. announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.
RFK Jr. announces end to some mRNA contracts, including for flu, covid
The targeting of the vaccine technology once considered revolutionary follows intense criticism by conservatives and anti-vaccine activists.
Republican senator claims RFK Jr. mRNA vaccine decision undermines Trump agenda
Sen. Bill Cassidy spoke out against HHS winding down mRNA vaccine development activity, asserting the move undermines the president's agenda
Stocktwits on MSN2d

Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.
BioSpace17d

Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, follows the pharma’s potential $1.4 billion COVID vaccine licensing deal with ...

HHS phases out mRNA vaccine trials for COVID-19, bird flu

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

Sanofi: Playing To Win

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Novavax raises annual revenue forecast on vaccine supply partnerships

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...
Stocktwits on MSN2d

Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not ...